Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
The potential for cobalt(III) complexes in medicine, as chaperones of bioactive ligands, and to target tumours through bioreductive activation, has been examined over the past 20 years. Despite this, chemical properties such as reduction potential and carrier ligands required for optimal tumour targeting and drug delivery have not been optimised. Here we review the chemistry of cobalt(III) drug design, and recent developments in the understanding of the cellular fate of these drugs.
Hall
Matthew D
MD
Centre for Heavy Metals Research, School of Chemistry, The University of Sydney, NSW 2006, Australia.
Failes
Timothy W
TW
Yamamoto
Natsuho
N
Hambley
Trevor W
TW
D000970:Antineoplastic Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003035:Cobalt / Q000494:pharmacology*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D000860:Hypoxia; D008024:Ligands; D018832:Molecular Chaperones / Q000737:chemistry*; D015394:Molecular Structure; D011485:Protein Binding; D013329:Structure-Activity Relationship